# EDGAR Filing Document

**Accession Number:** 0001761918
**File Stem:** 0000950170-25-090493
**Filing Date:** 2025-6
**Character Count:** 5347
**Document Hash:** c0c4b66c4ea10b2c513e28a00007aaf1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-090493.hdr.sgml**: 20250626

**ACCESSION NUMBER**: 0000950170-25-090493

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 10

**CONFORMED PERIOD OF REPORT**: 20250624

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250626

**DATE AS OF CHANGE**: 20250626

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Erasca, Inc.
- **CENTRAL INDEX KEY:** 0001761918
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831217027
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40602
- **FILM NUMBER:** 251081200

**BUSINESS ADDRESS:**
- **STREET 1:** 10835 ROAD TO THE CURE, SUITE 140
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** (858) 465-6511

**MAIL ADDRESS:**
- **STREET 1:** 10835 ROAD TO THE CURE, SUITE 140
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## **FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** June 24, 2025<br>

------

Erasca, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-40602 | 83-1217027 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 3115 Merryfield Row<br>Suite 300 |  |  |
| San Diego**,** California |  | 92121 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (858) 465-6511<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.0001 par value per share | ERAS | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## **Item 5.07 Submission of Matters to a Vote of Security Holders.** 
On June 24, 2025, Erasca, Inc. (the Company) held its annual meeting of stockholders (the Annual Meeting). As of the close of business on April 28, 2025, the record date for the Annual Meeting, there were 283,287,382 shares of common stock entitled to vote, of which there were 241,830,362 shares present at the Annual Meeting in person or by proxy. At the Annual Meeting, stockholders voted on two matters as described briefly below and in more detail in the Company's definitive proxy statement dated April 29, 2025. The voting results were as follows:

*Election of three two Class I Directors for a term of three years expiring at the 2028 annual meeting of stockholders*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| Jonathan E. Lim, M.D. | For | 196988691 | &nbsp;&nbsp;&nbsp;&nbsp;Withheld | 2188603 | Broker Non Votes | 42653068 |
| James A. Bristol, Ph.D. | For | 178363384 | &nbsp;&nbsp;&nbsp;&nbsp;Withheld | 20813910 | Broker Non Votes | 42653068 |
| Valerie Harding – Start, Ph.D. | For | 177003177 | &nbsp;&nbsp;&nbsp;&nbsp;Withheld | 22174117 | Broker Non Votes | &nbsp;&nbsp;&nbsp;&nbsp; 42653068 |

---

The three nominees for Class I Director were elected.

*Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025*

For 240,251,523 Withheld 1,272,045 Against 306,794

There were 0 broker non-votes for this proposal.

The appointment of KPMG LLP was ratified.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | Erasca, Inc. |
| Date: | June 26, 2025 | By:  | /s/ Ebun Garner |
|  |  |  | Ebun Garner, General Counsel |

---

------